StemCell Therapy

The question remains unanswered as to whether a peer-to-peer collaborative model will prosper where medtech companies that are in some instances one step ahead of big pharma in terms of drug development are happy to be a third- party provider to big pharma that have the budgets and networks to truly deliver the regenerative medicine revolution.

In a recent document published by the UK government in response to the Regenerative Medicine Inquiry by the House of Commons Science and Technology Committee, policymakers stressed the importance of commercialising new therapies to meet the changing needs of the health sector.

In the UK, the Regenerative Medicine Expert Group (RMEG) has been tasked with developing an NHS regenerative medicine strategy to ensure the NHS is fully prepared to deliver innovative treatment and that regulations support and not hinder its delivery.

The Cell and Gene Therapy Catapult is also continuing to work to bridge the gap between translational research and commercialisation.

However, for the UK to be well-positioned to offer safe and effective regenerative therapies, a strategy is needed that covers the whole value chain from academic research, commercial development and clinical application.

The effect of Brexit on the UKs regenerative medicine sector remains unclear, but the UK has the opportunity to develop an independent framework outside the EU regulatory system to accelerate the development of new therapies and its economic potential while upholding the highest patient safety standards.

In any case, EU and UK regulators need to prioritise the standardisation of regulations governing manufacturing, quality control and the supply chain to keep up with advancements made by the FDA in the US.

Establishing an efficient supply chain for regenerative medicine

The promise of regenerative medicine requires an innovative look at the complete product life cycle, including the development of an efficient distribution network.

Once these novel drugs become mainstream, the entire healthcare ecosystem will have to adapt. Regulatory approval for any drug relies on it safely and successfully fulfilling its medical intent.

As such, information about supply chain management needs to be submitted to the regulator after the completion of phase 3 clinical trials, including packaging, labelling, storage and distribution.

The clinical supply chains required to deliver these therapies are arguably the most complex the industry has seen so far. Regenerative medicine is either personalised or matched to the donor-recipient. They are also highly sensitive to exogenous factors like time and temperature.

Advanced IT solutions and monitoring systems are being developed and employed to ensure end-to-end traceability. These are giving clinicians access to view the progress of therapies and their distribution in real-time and allow users to automatically schedule or amend material collections in line with manufacturing capacity, helping to keep the supply chain as agile as possible.

The live tissues and cells which form the basis of regenerative medicine products are highly sensitive and some have a shelf life of no more than a few hours.

Therefore, materials need to be transported from the site of harvest to manufacturing facilities, and from manufacturing facilities to medical institutions under strictly controlled conditions, within certain times and temperatures, according to cell and tissue requirements.

Temperature-controlled logistics solutions are vital to ensure a safe, effective and financially viable supply chain network for these high-value shipments. Cryopreservation is one technique increasingly being used to deliver medicines at optimum temperature using vapour phase nitrogen; however, many clinical settings remain ill-equipped to handle such equipment.

On-site production is an alternative manufacturing arrangement, particularly for autologous products which are derived from a patients own cells.

However, this throws up a number of compliance and infrastructure challenges, as the hospital would need to comply with a host of regulations including installing a Good Manufacturing Practice (GMP)-licensed clean room.

As a first-generation technology, stakeholders will have a greater tolerance for higher pricing... but only for a limited time period. By streamlining the currently very expensive manufacturing process and improving supply chain management, yields will automatically get larger and costs will slowly come down.

While there are many challenges in the road ahead, 2019 certainly appears to be the start of regenerative medicines move to the big time.

Read more:
Delivering the promise of regenerative medicine - PMLiVE

New York City, NY: November 05, 2019 The recent update in WorldwideRegenerative Medicine Market begins with description of the merchandise, definition, classification specifications and scope of product Regenerative Medicine market outlook. The Regenerative Medicine report provides forecast amount from 2019 to 2028. It also includes a radical analysis of worldwide market static knowledge, growth factors and geographical region-wise analysis, the highest manufacturers/major players.

It analyse historical Regenerative Medicine market values to figure on latest market wants and estimate future market propensity. It compose of development plans and policies of every and key players at the side of their producing processes and distinct approaches used throughout the method.

The report systematically specialize in competitive analysis of Regenerative Medicine market that disclose prime competitors concerned in marketing and marketing of market merchandise. This research report can provide associate degree detailed and complete info to the readers of Regenerative Medicine market. It conjointly serves a actual analysis of parent market of business with the assistance of past, gift and future market info.

To access the sample report, click here:https://marketresearch.biz/report/regenerative-medicine-market/request-sample

which can be helpful to require decisive judgement of business on Regenerative Medicine market and increase the ratio. the primary five-year accumulative revenue (20192023) of Regenerative Medicine market is projected to be US$ XX Mn, and latter 5 years (20242028) revenue is projected to be US$ XX Mn is calcualted during this report.

Vital Regions that operate Regenerative Medicine market covers geographic region (colombia, Argentina and Brazil), North America (Mexico, North American nation and also the United States), Regenerative Medicine market in Asia-Pacific (China, Japan, Korea, Republic of India and South-East Asia), (UK, Russia, FRG and Italy), the center East and continent (South Africa, UAE, Egypt and Saudi Arabia). Besides, production worth and volume, Regenerative Medicine market share, Regenerative Medicine value, import/export particularisation,SWOT analysis,Regenerative Medicine market growth analysis and price/cost.

Global Regenerative Medicine Market 2019 covers following leading manufacturers:

Organogenesis Inc, Osiris Therapeutics Inc, Pfizer Inc, Novartis AG, Vericel Corporation, NuVasive Inc, Cook Biotech Inc, GlaxoSmithKline plc., Boehringer Ingelheim GmbH, Amgen Inc

Key features of Regenerative Medicine market:

Elaborated data of Regenerative Medicine market opportunities, growth, prohibiting and risk study.

Moreover an entire analysis of existing and rising markets Regenerative Medicine market segments.

Leading market Regenerative Medicine players are present within the report.

The advance market tendencies, startegies and technologies have accelerated range of enterprise models and firms across the world.

Correct arrangement of Regenerative Medicine market is completed on the premise of segments, market size and share.

The information serves during this analysis report isnt solely descriptive in terms of amount however additionally quality.

Every and each Regenerative Medicine data collect from secondary sources are cross examined many times throughout paid primary interviews and business skilled expertize.

Enquire about our Regenerative Medicine report with our industry specialist:https://marketresearch.biz/report/regenerative-medicine-market/#inquiry

The research methodology used to obtained crucial information for Regenerative Medicine market:

1. The analysis methodology of Regenerative Medicine market includes not solely primary however additionally secondary research info sources. It perform distict factors moving business like market setting, varied government policies, historical information and latest trends, technological advancement,market restrains, market risk factors, future innovations,challenges, opportunities and any technical evolution in business.

2. Analysis analysts at first collect the data from distict trivial Regenerative Medicine info sources like monetary reports of the corporate, internet, magazines and analysis reports.

3. The fetched Regenerative Medicine market information is verified and even to assure its quality. varied quality testing techniques are accustomed guarantee its quality of Regenerative Medicine market. theyre approved by attending, conducting and direct interviews and questionnaires with Regenerative Medicine companys business executive, market main opinion leaders, market specialists and business executives.

4. At the end, the info is drawn in pictorial method within the type of tables, bar graphs, pie-charts and figures format. totally different methods are accustomed collect information concerning Regenerative Medicine market size covers high down and bottom-up approach.

5. Resulting a part of the Regenerative Medicine report provides a listing of manufacturers/distributors, information sources, analysis findings, and postscript.

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at[emailprotected].

More here:
Regenerative Medicine Market Risk Factors, Growth Analysis, Market Size and Innovations By 2028 - 5Gigs News

HAIFA, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the RESTORE Consortium is hosting its 1st Advanced Therapies Science Meeting (ATSM), which is being held November 25-26, 2019 in Berlin. As a leading member of the large-scale research initiative, Pluristem, along with additional respected members, is committed to accelerating the availability of advanced therapies to all those in need, a main motivation standing behind RESTORE.

Led by Charit-Universittsmedizin Berlin, and coordinated by Professor Hans-Dieter Volk from the BIH-Center for Regenerative Therapies in Berlin, RESTORE aims to promote groundbreaking research, drive Europe to the forefront in advanced therapies and deliver a pipeline of potentially transformative cures to patients in need. Advanced Therapies are a potential game changer in health care, aiming to shift our focus from chronic treatment of disease to regeneration of health, said Prof. Volk. We are determined to translate promising research findings into safe therapies, and we are working across disciplines and national borders in order to achieve this goal. The 1st Advanced Therapies Science Meeting provides the opportunity to discuss the still numerous obstacles in the way of implementing these promising therapies in routine clinical care.

This initiative may hold the key for changing the approach towards medicine in Europe, and advancing solutions for patients in need, said Zami Aberman, Executive Chairman of Pluristem. The European Commission is poised to make a significant investment of up to 1 billion in a consortium of companies that can drive forward the development of novel regenerative therapies, and we are pleased to be a leading part in this effort. Given our proprietary cell manufacturing technology and broad, late-stage pipeline, we believe we can play a key role toward making the transforming promise of advanced therapies into a reality.

The 1st ATSM will bring together experts from industry, patient organizations and academia to discuss the challenges within the field of advanced therapies, which include gene and cell therapies and tissue-engineering approaches. The ATSM is focused on trying to drive forward a concerted interdisciplinary effort, making use of science, infrastructure and funding within Europe to make regenerative therapies available to the broadest possible patient population.

The two-day program will include talks from Nobel Prize winner Ada Yonath (Director of Weizmann Institute of Science, Israel), Michele De Luca (University of Modena, Italy), Timothy OBrien (National University of Ireland, Galway, Ireland), Maksim Mamonkin (Baylor College of Medicine, USA), Manuela Gomes (University of Minho, Portugal) and others.

RESTORE partners include the Charit Universittsmedizin Berlin and Berlin Institute of Health (Germany), the University of Zurich (Switzerland), Cell and Gene Therapy Catapult (United Kingdom), TissUse GmbH (Germany), Pluristem (Israel), Miltenyi Biotec GmbH (Germany), INSERM Institut National de la Sant et de la Recherche (France), Innovation Acta S.r.l. (Italy), Fondazione Telethon Milan (Italy), and the University of Minho (Portugal).

About Pluristem TherapeuticsPluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.

Safe Harbor StatementThis press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses the potential for the RESTORE Consortium to receive up to a 1 billion award by the European Commission and the timing of the potential award, that RESTOREs aim is to promote groundbreaking research, drive Europe to the forefront in advanced therapies and deliver a pipeline of potentially transformative cures to patients in need, that RESTORE and the 1st ATSM may hold the key for changing the approach towards medicine in Europe, and advancing solutions for patients in need, and its belief that given its proprietary cell manufacturing technology and broad, late-stage pipeline, it believes it can play a key role toward making the transforming promise of advanced therapies into a reality. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristems products may not be approved by regulatory agencies, Pluristems technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristems process; Pluristems products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristems patents may not be sufficient; Pluristems products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

View post:
RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare -...

Posted By MyUVicLife on Oct 30, 2019 in Hands-on learning, Student life

On the weekend of October 4th, our team participated in this years Health and Regenerative Medicine Hackathon. We thought we would give a quick recap of the event as well as share our experience with you.

By: Natalie Koehn, Jacqui Moreland, Kim Arklie and Jacky Le

The second annual Health and Regenerative Medicine Hackathon was held at FortTectoriain downtown Victoria during the first weekend of October.

Traditionally, a hackathon is a competition where people gather to tackle coding and programming related challenges in a consecutive period of 24-48 hours. However, the Health and Regenerative Medicine Hackathon is different! The challenges as its name suggests are related to health and medicine. Due to the nature of the challenges, competitors were allowed to work on their designs during the month leading up to the Hackathon weekend.

The following challenges were presented to us by various organizations involved in Victorias health industry:

As a combined team of biomedical and mechanical engineers from the University of Victoria, we are passionate about creating assistive technology to solve health-related problems. We had worked together in a school group project in the past and were looking to find another opportunity to work together and design something meaningful.

Inspired by their patient stories and their mission to provide low-cost healthcare opportunities to developing countries, we were eager to take on the Victoria Hand Projects (VHP) challenge to create an assistive device to allow children to write.

A 3D printed solution was optimal for both the rapid prototyping of the Hackathon but also was one of the design requirements for the given project.

In the two weeks leading up to the Hackathon, we came up with a general design concept consisting of two major components an attachment mechanism to the prosthetic hand and a clamping mechanism for the writing utensil. A few iterations were made as a result of tests performed on our original design.

This led us to our final product that utilizes a three-prong and elastic mechanism to grasp the pencil. The pencil is housed in a cylindrical tube, held in place at an optimal angle, that attaches to a simple support that wraps around the bottom of the hand. The hand rests on a bed of silicone at the base of the device in order to prevent unwanted movement, and tightly secured with avelcrostrap.

It was inspiring coming together on the final day of the Hackathon to see the hard work of each group come to life to create such a wide range of solutions. The panel of judges, sponsors and professionals that attended the event were just as passionate about the projects as we were. They provided feedback and support to the teams throughout the Hackathon and helped make the event possible.

All in all, it was a great opportunity and we are looking forward to participating in next years Hackathon. We encourage anyone who is interested in STEM related fields to engage in opportunities like this and explore the design world in a fun, out of school environment!

The views expressed in this blog are my own, and do not necessarily reflect the policies or views of the University of Victoria. I monitor posts and comments to ensure all content complies with the University of Victoria Guidelines on Blogging.

More:
2019 Health and Regenerative Medicine Hackathon - University of Victoria News

GERMANTOWN, Md., Nov. 4, 2019 /PRNewswire/ -- Intrexon Corporation(NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release third quarter financial results before the market opens on Tuesday, November 12th, 2019. Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients and a wholly owned subsidiary of Intrexon, will host a conference call that day at 11:00 AM ET to provide Precigen business and pipeline updates.

The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada), and 1412-317-6061(International) and providing the number 4454504 to join the Precigen Business and Pipeline Update Call. Participants may also access the live webcast through Intrexon's website in the Investors section at http://investors.dna.com/eventsor Precigen's website in the Presentations section at https://precigen.com/media/#id-presentations.

About Intrexon Corporation Intrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with Better DNA to create biologically-based products that improve the quality of life and the health of the planet through two operating units Intrexon Health and Intrexon Bioengineering. Intrexon Health is focused on addressing unmet medical needs through a diverse spectrum of therapeutic modalities, including gene and cell therapies, microbial bioproduction, and regenerative medicine. Intrexon Bioengineering seeks to address global challenges across food, agriculture, environmental, energy, and industrial fields by advancing biologically engineered solutions to improve sustainability and efficiency. Our integrated technology suite provides industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA, and we invite you to discover more at http://www.dna.comor follow us on Twitter at @Intrexon, on Facebook, and LinkedIn.

About Precigen : Advancing Medicine with Precision Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cellular therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Precigen also follows the science opportunistically in pursuit of promising programs in emerging therapeutics. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization. Precigen was founded as a wholly owned subsidiary of Intrexon Corporation(NASDAQ: XON) and leverages a diverse portfolio of technology platforms to advance human health. For more information about Precigen, visit http://www.precigen.comor follow us on Twitter @Precigenand LinkedIn.

Trademarks Intrexon, Powering the Bioindustrial Revolution with Better DNA,and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information contact:

Intrexon Investor Contact:

Steven Harasym

Vice President, Investor Relations

Tel: +1 (301) 556-9850

investors@dna.com

Intrexon Corporate Contact:

Marie Rossi, PhD

Vice President, Communications

Tel: +1 (301) 556-9850

publicrelations@dna.com

Precigen Media Contact:

Donelle M. Gregory

press@precigen.com

Continued here:
Intrexon to Announce Third Quarter Financial Results on November 12th - Herald-Mail Media

SELBYVILLE, Del., Nov. 5, 2019 /PRNewswire/ -- The global Cancer Gene therapy market'srevenue is expected to surpass USD $2.5 billion by 2025, according to a new research report by Global Market Insights, Inc. Rising government initiatives in emerging economies for promoting developments in gene therapies will positively impact the cancer regenerative medicine market's growth. The government often implements several laws and initiatives to motivate scientists and researchers to perform extensive analysesof gene therapies. Furthermore, the government also funds various studies that are carried out for developing molecular therapies utilized in the treatment of cancer. The aforementioned factors should escalate the industry's growth.

There have been several advancements in the biotechnology sector that have proven beneficial for the industry's growth. Several viral vectors have been introduced in the market that work efficiently for carrying out gene transfers. Researchers vigorously work on studying the efficacy and efficiency of the viral, as well as non-viral, vectors that are utilized in gene therapy. Newly developed viral vectors are capable of inhibiting the growth of tumor-inducing genes and are preferred by biopharmaceutical companies. Moreover, healthcare professionals working on gene therapy have started trusting and preferring these viral vectors for treating cancer patients. Therefore, growing advancements will ensure the availability of superior quality vectors for gene transfer, which will foster the market's growth.

Request for a sample of this research report athttps://www.gminsights.com/request-sample/detail/763

The types in the cancer gene market are categorized into in-vivo and ex-vivo. The in-vivo segment of the cancer gene therapy market was valued over USD $350 million in 2018 and will experience substantial growth throughout the analysis period. In-vivo gene therapy is a cost-effective option since it avoids the tedious process of removing cells from a patient's body. Furthermore, in-vivo cancer gene therapy is widely expected to treatcystic fibrosis, which positively influences business growth. However, in recent times, several high-profile, adverse events pertaining to gene therapies were recorded that has reduced its demand, therebylowering the pace of segmental growth.

Based on product, the global market is bifurcated into viral vectors and non-viral vectors. The viral vectors segment of cancer gene therapy is anticipated to foresee around 23% growth throughout the analysis timeframe. Adenovirus is one of the highly preferred viral vectors that has commendable transductional efficiency that raises its adoption. Moreover, theadenovirus vector reduces the risk of mutagenesis. Besides, other viral vectors are also efficient and enable long-term DNA expression, reducing the mortality rate in patients suffering from cancer. The aforementioned factors will spur the viral vectors' segment growth.

Cancer Gene Therapy Market Growth, By Product

5.1. Key segment trends

5.2. Viral vectors5.2.1. Market size, by region, 2014 2025 (USD Million)5.2.2. Adenoviruses5.2.2.1. Market size, by region, 2014 2025 (USD Million)5.2.3. Lentiviruses5.2.3.1. Market size, by region, 2014 2025 (USD Million)5.2.4. Retrovirus5.2.4.1. Market size, by region, 2014 2025 (USD Million)5.2.5. Adeno associated virus5.2.5.1. Market size, by region, 2014 2025 (USD Million)5.2.6. Herpes simplex virus5.2.6.1. Market size, by region, 2014 2025 (USD Million)5.2.7. Vaccinia virus5.2.7.1. Market size, by region, 2014 2025 (USD Million)5.2.8. Others5.2.8.1. Market size, by region, 2014 2025 (USD Million)

5.3. Non-viral vectors5.3.1. Market size, by region, 2014 2025 (USD Million)

5.4. Others5.4.1. Market size, by region, 2014 2025 (USD Million)

Browse key industry insights spread across 95 pages, with 120 market data tables and eight figures and charts from the report,Cancer Gene Therapy Market Size By Type (Ex-vivo, In-vivo), By Product (Viral Vectors {Adenoviruses, Lentiviruses, Retrovirus, Adeno Associated Virus, Herpes Simplex Virus, Vaccinia Virus}, Non-viral Vectors), By End-use (Biopharma Companies, Research Institutes), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, U.K., France, Italy, Spain, Japan, China), Price Trends, Application Potential, Competitive Market Share & Forecast, 2019 2025," in detail, along with the table of contents:

https://www.gminsights.com/industry-analysis/cancer-gene-therapy-market

The end-use segment of cancer gene therapy includes biopharmaceutical companies, research institutes and others. The research institutes segment held around a 40% revenue share in 2018. Significant segmental growth can be attributed to the increasing demand for viral vectors by research institutes that work on cancer gene therapies. Research institutes constantly focus on assessing the efficacy of gene therapies by using different vectors. Moreover, vector manufacturing companies develop superior quality viral, as well as non-viral, vectors that will positively influence the segmental growth.

The U.K. market accounted for around USD $35 million in 2018 and is projected to witness momentous growth during the analysis timeframe. The increasing adoption of cancer gene therapy due to considerably high purchasing power has augmented the cancer gene therapy market growth in the country. Furthermore, the increasing prevalence of cancer has positively influenced the industry's growth. According to a study, in 2017, around 164,901 people died from cancer in the U.K., which creates demand for advanced gene therapies for treating cancer.

Make an inquiry for purchasing this report athttps://www.gminsights.com/inquiry-before-buying/763

Browse Related Reports:

Cancer Diagnostics Market Statistics 2025: Breast cancer is one of the most frequent cancers among womenacross the globe. According to the World Health Organization (WHO), about 2.1 million women are suffering from breast cancer each year. Also, breast cancer rates are higher among women in more developed countries than in developing and under-developed economies. A few prominent players operating in the global market are Abbott, Roche, Siemens Healthcare, Danaher Corporation, Becton, GE Healthcare, Dickinson and Company (BD), Janssen Diagnostics among others.

https://www.gminsights.com/industry-analysis/cancer-diagnostics-market

About Global Market Insights

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:

Arun HegdeCorporate Sales, USAGlobal Market Insights, Inc.Phone:1-302-846-7766Toll Free:1-888-689-0688Email:sales@gminsights.com

Related Images

cancer-gene-therapy-market.jpg Cancer Gene Therapy Market Forecasts 2025 Cancer Gene Therapy Market is set to register over a 22% CAGR up to 2025, driven by the rising prevalence of cancer in developed, as well as developing, economies.

Related Links

Cancer Gene Therapy Market size

Cervical Cancer Diagnostic Market

SOURCE Global Market Insights, Inc.

https://www.gminsights.com

View post:
Cancer Gene Therapy Market Value to Hit $2.5 Billion by 2025: Global Market Insights, Inc. - PRNewswire

Toronto, ON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that creates allogeneic (donor) gene-edited T cells from stem cells on an industrial scale, efficiently making T cell therapies that are clinically robust and of a consistently high quality. Notch is actively pursuing industry partnerships.

The founders of Notch - Sunnybrook Health Sciences Centre, University of Toronto (UoT), Toronto Innovation Acceleration Partners (TIAP) and CCRM, with Lumira Ventures as an additional investor - created Notch to provide a vehicle through which to further develop and bring to market the combined pioneering research, nearly ten years underway, from the labs of Drs. Juan CarlosZiga-Pflcker,Senior Scientistin Biological Sciences atSunnybrook,and Chair of the Department of Immunology atUoT;andof Peter Zandstra,Professor, Institute of Biomaterials and Biomedical Engineering at UoTandDirector, School of Biomedical engineering and Michael Smith Laboratories at the University of British Columbia.

"This technology is very promising and might be used to create therapiesto treatsome of our greatest medical challenges,like cancer, autoimmune diseases and organ transplant rejection. Its also the first and only method that can reconstitute immune systems," says Dr. Andy Smith, President and CEO of Sunnybrook Health Sciences Centre. "Finally having optionstotarget these high-impact areasfor our patientsis what we mean when we say we are inventing the future of health care."

Jennifer Fraser, Director Innovations at the University of Toronto, comments that "Dr. Ziga-Pflckers allogeneic T cell therapy was one of the first projects I worked on when I joined UoT. Its very gratifying to see the technology move toward the clinic."

Even as the field for these therapies grows rapidly, major challenges have until now prevented wider adoption mainly due to a slow and expensive manufacturing process which yielded variable results. The Notch technology, however, shows promise for surmounting these issues cost-effectively and reliably. Notch, having been incubated at CCRM, will be able to leverage its in-house process development expertise and Good Manufacturing Practices (GMP) facility, located in downtown Toronto. It offersuniversally enhanced T cell therapies against high-impact diseases, using stem cells as a renewable source to expand treatment options and deliver cost-effective immunotherapies to patients. The aim of Notch is to generate T cells from multiple sources of stem cells and provide a platform for research and development, and a better way of manufacturing T cells and their applications for treating cancers or immune deficiencies.

"TIAP is pleased that, after many years of nurturing this research and investing in the risky early-stages with our co-founders, we are now seeing a truly ground-breaking new health science technology make its way through development in a very encouraging way. This is yet another example of what can be done through TIAPs unique ability within the community to bundle technologies across multiple institutions. This is a true collaboration which has resulted in development of a technology that will have significant impact", says Dr. Rafi Hofstein, President & CEO of TIAP.

"Notch Therapeutics is a star pupil in CCRMs incubation program," says Dr. Michael May, President and CEO of CCRM. "By de-risking the technology and designing Proof of Concept studies to appeal to investors, attracting experienced start-up management, and working with our ecosystem partners, we have collectively given Notch every opportunity to succeed."

Dr. Benjamin Rovinski, Managing Director of Lumira Ventures, states: "Early on, our team recognizedNotchs novel and differentiated platform and its potential to produce safer, more effective, and scalable allogeneic T cell therapies. We are pleased to be part of the financing syndicate. The quality and breadth of science coming out of Canadian universities is phenomenal, and important innovators like Notch are able to access capital, knowledge and the engaged support of Lumira and other investors, to enable the development and commercialization of their technology. We are excited to work with the entire Notch team."

About TIAP

TIAP is a leading provider of venture building services, early-stage funding, and deal-brokering with industry and private investors. As a member-based organization made up of 14 member institutions including University of Toronto and affiliated teaching hospitals TIAPs mandate is to drive the commercialization of their most promising research breakthroughs. TIAP has an active portfolio of more than 60 companies in sectors such as therapeutics, medical devices and IT/AI, which have raised in excess of CDN$300M from global investors, and has created more than 1000 direct/indirect jobs.

For more information, please visit http://www.tiap.ca

About University of TorontoFounded in 1827, the University of Toronto is Canadas leading institution of learning, discovery and knowledge creation. U of T is one of the worlds top research-intensive universities, driven to invent and innovate. It is also one of the top five universities in the world for its start-up incubator programs. In the last 10 years, the U of T entrepreneurship community has created over 500 companies and raised over $1.5 billion in investment capital. http://www.utoronto.ca

About Sunnybrook Health Sciences CentreSunnybrook Health Sciences Centre is inventing the future of health care for the 1.3 million patients the hospital cares for each year through the dedication of its more than 10,000 staff and volunteers. An internationally recognized leader in research and education and a full affiliation with the University of Toronto distinguishes Sunnybrook as one of Canadas premier academic health sciences centres. Sunnybrook specializes in caring for high-risk pregnancies, critically-ill newborns and adults, offering specialized rehabilitation and treating and preventing cancer, cardiovascular disease, neurological and psychiatric disorders, orthopaedic and arthritic conditions and traumatic injuries. The Hospital also has a unique and national leading program for the care of Canadas war veterans. For more information about how Sunnybrook is inventing the future of health care. Please visit us online at http://www.sunnybrook.ca

About CCRMCCRM, a Canadian not-for-profit organization funded by the Government of Canada, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, dedicated funding, and unique infrastructure. CCRM is the commercialization partner of the Ontario Institute for Regenerative Medicine and the University of Torontos Medicine by Design. CCRM is hosted by the University of Toronto. Visit us atccrm.ca.

About Lumira VenturesLumira Ventures isCanadasleading and most active healthcare venture capital firm. Lumira invests in best-in-class North American companies developing innovative therapeutics and medical technologies whose products offer transformative improvements to patient health outcomes and provide meaningful reductions to the overall cost of healthcare delivery. Since inception, Lumiras portfolio companies have brought 50+ new therapies to market, impacting the lives of 1+ billion patients globally, generating $65+ billion in cumulative revenue.

For more information, please visit http://www.lumiraventures.com

See the rest here:
Notch Therapeutics a new company with a revolutionary allogeneic ("off the shelf") T cell technology - GlobeNewswire

As a member of the daytime community for many years, Don Diamont has seen soaps tackle important social issues. Now, the star of The Bold and the Beautiful is lending his name to a topical and vital concern.

The actor was invited recently to speak at the annual ISSCR (International Society for Stem Cell Research Conference) in Los Angeles. He accepted to show his support for a dear pal, who is battling ALS.

I was touched, and humbled to be asked to speak for, and about my beloved friend Nanci Ryder at this years ISSCR Conference, Diamont posted on his Instagram account. The event is the largest gathering of stem cell scientists and clinicians in the world. Nancis story is a powerful one, and I was honored to have an opportunity to share it with those on the front lines in the battle to find a cure for ALS.

Yesterday, at The Walk to Defeat ALS, I was with Nanci and the group of wonderful souls that make up TEAM NANCI, Diamont continued. Thank you to the @alsagoldenwest chapter for all that you do! Thank you to Dr. Justin Ichida! Justin is the Assistant Professor of Stem Cell and Regenerative Medicine at the Keck School of Medicine USC. Hes making significant strides in moving toward a cure for ALS. Finally, to anybody out there whos helping in any way to fight the good fight in eliminating this horrible illness, thank you!

Diamont concluded his post with words of encouragement for his friend: Nanci, you are the bravest of the brave! I, and we LOVE YOU

Soap fans may recall that the late Michael Zaslow (ex-Roger, Guiding Light; ex-David, One Life to Live) had been diagnosed with the disease. He passed away in 1998. For more information on ALS, click here. The Bold and the Beautiful airs weekdays on CBS. Check local listings for air times.

View this post on Instagram

I was touched, and humbled to be asked to speak for, and about my beloved friend Nanci Ryder at this years ISSCR Conference. The event is the largest gathering of stem cell scientists and clinicians in the world. Nancis story is a powerful one, and I was honored to have an opportunity to share it with those on the front lines in the battle to find a cure for ALS. Yesterday, at The Walk to Defeat ALS, I was with Nanci and the group of wonderful souls that make up TEAM NANCI. Thank you to the @alsagoldenwest chapter for all that you do! Thank you to Dr. Justin Ichida! Justin is the Assistant Professor of Stem Cell and Regenerative Medicine at the Keck School of Medicine USC. Hes making significant strides in moving toward a cure for ALS. Finally, to anybody out there whos helping in anyway to fight the good fight in eliminating this horrible illness, thank you! Nanci, you are the bravest of the brave! I, and we LOVE YOU

A post shared by Don Diamont (@dondiamont) on Nov 4, 2019 at 4:15pm PST

03:31

Dollar Bill Tribute

Video Credit: SunRiseIta

See original here:
The Bold and the Beautiful Star Don Diamont Supports ALS Research - Soap Hub

- Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basis

- Partnership incorporates Cryoport's Cryoportal Logistics Management Platform, SmartPak II Condition Monitoring System and Cryoport's unique Chain of Compliance for regulatory solutions.

- Partnership builds on the recently announced partnership between Lonza and Vineti with an aim to provide cell and gene therapy developers with a fully integrated delivery solutions including manufacturing, supply chain orchestration and logistics, globally

BASEL, Switzerland and IRVINE, Calif., Nov. 5, 2019 /PRNewswire/ --

Quote from Alberto Santagostino, SVP Head of Cell & Gene Technologies, Lonza Pharma & Biotech:"The Lonza-Cryoport collaboration is an enabling part of a wider goal for Lonza to create a network of strategic partnerships and capabilities that enable seamless vein-to-vein delivery of cell and gene therapies for its customers and their patients. There is no doubt that this partnership enables us to provide a best-in-class solution to cell and gene therapy companies for manufacturing and supply chain services, allowing us to provide a fully integrated solution that reduces risk and increases transparency."

Quote from Jerrell Shelton, CEO, Cryoport:"Clinical trial activity in the cell and gene therapy sector is rapidly growing as biopharmaceutical companies discover new ways to harness regenerative therapies and combat illnesses. As more and more of these therapies approach commercialization, there is strengthening demand for reliable, integrated outsourced manufacturing and distribution solutions. Our partnership agreement with Lonza, an internationally-renowned supplier to the pharma and biotech markets, will improve effectiveness, efficiency and safety throughout the cell and gene therapy manufacturing process by integrating our temperature-controlled supply chain solutions with Lonza's manufacturing services."

Lonza (LONN.SW) and Cryoport, Inc. (CYRX) ("Cryoport"),announced today their partnership in the cell and gene therapy field and across Lonza's 'vein-to-vein' delivery network. As a part of this commitment, Lonza announced Cryoport as its preferred partner in the transport and delivery of patient tissues on a global basis, with the continued goal of seamless service for Lonza's customers and their patients. Lonza and Cryoport will work to remove the supply chain hurdles faced by developers of personalized therapeutics -- including autologous therapies, matched-allogeneic therapies, and personalized cancer vaccines -- as they prepare for the commercial launch of their respective therapies.

Lonza's network of cell and gene therapy facilities spans the US, Europe and Asia and serves both clinical and commercial customers globally. Cryoport currently supports over 413 clinical trials and 3 commercial therapies in the regenerative medicine space and operates in over 100 countries around the world. Integrating Cryoport's logistics andbioservices solutions with Lonza's manufacturing services and expertise will ensure a trusted and seamless supply chain and drive efficiencies in delivering innovative medicines to patients.

The goal of the partnership is to provide fully integrated solutions including, but not limited to, co-location of manufacturing, bioservices and distribution facilities to improve and enhance responsiveness and optimized product workflow, automated data management providing integrated data entry, and process optimization that reduces risk, increases transparency and improves certainty.

Story continues

Cryoport's logistics system aims to provide Lonza's clients with reliable and comprehensive delivery solutions through its advanced technologies, Global Supply Chain Network and dedicated scientists, technicians and supporting teams of professionals. Beyond Cryoport's proprietary Cryoport Express Shippers, this partnership incorporates Cryoport's Cryoportal Logistics Management Platform and SmartPak II Condition Monitoring System, which brings to the market an integrated IT solution that provides risk mitigation and Cryoport's unique Chain of Compliance for regulatory solutions.

About Lonza Lonza is an integrated solutions provider that creates value along the Healthcare Continuum. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found atwww.lonza.com.

About CryoportCryoport, Inc. (CYRX) is the world'spremier provider of temperature-controlled supply chain solutions for the life sciences industry,serving the Biopharma, Human Reproductive, and Animal Health markets. Our mission is to support life and health on earth by providing reliable and comprehensive solutions for the life sciences through our advanced technologies, Global Supply Chain Network and dedicated scientists, technicians and supporting team of professionals. Through purpose-built proprietary packaging; information technology; smart, sustainable cold chain logistics; and biostorage/biobanking services, Cryoport helps its customers advance life sciences research, support life-saving advanced therapies and deliver vaccines, protein producing materials, and IVF treatments in over 100 countries around the world. For more information, visit http://www.cryoport.com or follow @cryoport on Twitter atwww.twitter.com/cryoport for live updates.

Additional Information and Disclaimer (Lonza)Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Forward Looking Statements (Cryoport)Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the Company's 10-K for the year ended December 31, 2018 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/lonza-partners-with-cryoport-and-strengthens-its-vein-to-vein-delivery-network-in-cell--gene-therapy-300950920.html

Read the original:
Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Delivery Network in Cell & Gene Therapy - Yahoo Finance

Masume Bayat,1 Seyed Ahmad Raeissadat,2 Maryam Mortazavian Babaki,3 Shahram Rahimi-Dehgolan4

1Physical Medicine and Rehabilitation Department of Mahdiyeh Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Clinical Development Research Center of Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Physical Medicine and Rehabilitation Department & Research Center, Shohada-E-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 4Physical Medicine and Rehabilitation Department of Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran

Correspondence: Maryam Mortazavian BabakiNo. 1989934148, Shohada-e-Tajrish Hospital, Tehran, IranTel +982122731112Fax +982122724210Email maryam_m.babaky@sbmu.ac.ir

Purpose: To compare the efficacy of dextrose prolotherapy versus steroid injection in the treatment of patients with chronic lateral epicondylitis.Methods: Thirty subjects with chronic lateral epicondylitis were randomly assigned into two groups of hypertonic dextrose or methylprednisolone injection. Participants were assessed through Quick DASH and VAS scores, once before injection, and then after 1- and 3-months follow-up. Two patients were excluded due to not completing the follow-up timepoints.Results: In both groups VAS scores revealed significant improvement during the first month follow-up [mean difference (MD) = 1.93.3, versus 1.51.9 for the prolotherapy and steroid groups, respectively]. This declining trajectory continued at the third month visit in the prolotherapy group and MD reached 4.42.9, while it did not change remarkably in the steroid group (MD=1.93.4). In fact, comparing VAS scores between the 1st- and 3rd-month time points did not reveal a significant improvement in the steroid group (p=0.6). Also, the Quick DASH index showed a similar pattern and improved remarkably in both groups during the first visit. However, only the efficacy in the prolotherapy group persisted after 3-month follow-up (MD = 9.521.6, p=0.044). One month after injections no preference between the two interventions was observed (p=0.74 for VAS and 0.14 for Quick DASH score). However, the 3rd-month follow-up revealed a meaningful superiority (p=0.03 for VAS and p=0.01 for Quick DASH score) favoring the prolotherapy method.Conclusion: Both methods were proven to be effective in the short-term treatment of chronic lateral epicondylitis, but dextrose prolotherapy seems to be slightly more efficacious than steroid injection over a longer period.Clinical trial registration: Iranian Registry of Clinical Trials Database: IRCT20170311033000N3.

Keywords: regenerative medicine, tennis elbow, methylprednisolone, prolotherapy

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Go here to see the original:
Is Dextrose Prolotherapy Superior To Corticosteroid Injection In Patie | ORR - Dove Medical Press

Last week, the Cystic Fibrosis Foundation launched a new initiative called Path to a Cure. A press release called it an ambitious research agenda to deliver treatments for the underlying cause of the disease and a cure for every person with cystic fibrosis (CF).

It added: The Foundation is challenging potential collaborators to submit proposals that will accelerate the pace of progress in CF drug discovery and development and intends to allocate half a billion dollars to the effort through 2025.

News of the initiative comes nine days after an announcement by the U.S. Food and Drug Administration that it has approved the highly anticipated treatment Trikafta, a triple combination therapy of ivacaftor, tezacaftor, and the new elexacaftor (VX-445). Trikaftas clinical trial outcomes were remarkable and on par with the early clinical results from the highly effective Kalydeco several years ago, especially when compared with the outcomes of the not very robust but efficacious Orkambi and Symdeko.

The foundations strategic plan for the next five years is audacious, but I think its an honest pursuit. A year ago, I wrote about what a cure for CF might look like, and I discussed how the progressive and chronic nature of CF makes curing it a sort of nebulous concept.

In CF, the broken protein that is the underlying cause of the disease isnt the killer. The killers are the recurring infections, the inflammation, and the downstream effects of the broken cystic fibrosis transmembrane conductance regulator (CFTR) protein. Due to recurring infections, the lungs become damaged, and endemic bacteria become more resistant to traditional antibiotics.

For someone with moderate lung disease, fixing the underlying issue wont heal the scar tissue or reconstruct damaged airways. Most people with CF are pancreatic insufficient. Theoretically, an embryonic cure would prevent sustained damage to any part of the body. Once birth occurs, however, a cure would be too late to prevent even the slightest damage.

In the column from last year, I also wrote: Im not saying a cure is impossible or undesirable. Rather, there are multiple pillars to ultimately curing all the ills that deeply affect our lives. I think looking at a cure in this way is a reason to be hopeful. I added that I didnt believe this change of perspective about what a cure looks like should be a reason for discouragement.

What I like about the CF Foundations Path to a Cure is how theyre discussing what the different paths look like. Current therapies are modulators. At best, they repair CFTR protein, which is different than fixing or replacing it. This initiative also emphasizes the most important tenet of all CF therapies: It is intended to help everyone with CF. Complicated mutations will require different strategies.

A cure for cystic fibrosis is a complicated endeavor. CF is a particularly interesting genetic disease for many reasons, not least of which is that the pathway to curing it could be extrapolated to other diseases with genetic causes or predispositions. I do believe a cure is possible, though Im usually cautious to offer my commentary on the word cure.

Many subpopulations exist in the CF community. Thousands of people in the world have CF. A percentage of that population doesnt have access to the most basic CF treatments. Many people in the United States dont even have good access or care. Modulators arent approved for transplant patients.

Its not for nothing that the CF Foundation and the community itself must ask one important question: What does life look like for someone with feeble lung function that is cured of CF? If other treatment plans arent in place such as better transplant strategies utilizing stem cells, or using stem cells for lung regeneration a cure may not prolong life, but rather prolong the misery of end-stage disease.

Part of planning for the future is predicting the effects of that plan. But we must ask: How are we giving everyone with CF the chance to live well into their 70s and 80s? I think the important discoveries made along the way will be instrumental in learning if its possible to repair diseased lungs through regenerative medicine.

Path to a Cure is one of the most exciting research agendas weve seen. Im looking forward to the day when the CF Foundation announces that a cure has been found.

Follow along with my other writings on my humbly named site, http://www.trelarosa.com.

***

Note: Cystic Fibrosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Cystic Fibrosis News Today, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to cystic fibrosis.

Read this article:
What We Should Expect from the CF Foundation's 'Path to a Cure' - Cystic Fibrosis News Today

A huge leap could be made with bioprinting the 3D printing of tissue and organs thanks to an innovative idea which proposes to use aqueous architectures, or in other words, printing in a specially made fluid.

As Science magazine reports, human tissue and organs are very tricky to make using traditional 3D printing methods without putting support scaffolding in place and that scaffolding can later be very difficult (or indeed impossible) to remove.

So the idea as advanced by Chinese researchers is to move away from a solid support structure, and instead use liquid. Specifically, this would be a fluid matrix into which the liquid design for an organ could be injected, and the surrounding fluid then drained away after the organ has set.

This kind of approach has previously been attempted, except the fluid matrix hasnt proven stable enough, and the whole thing has simply collapsed. So instead these researchers from China have used hydrophilic (attracted to water molecules) liquid polymers which are capable of creating a stable membrane.

Using this method, the liquid structure is far more robust and is even capable of holding its shape for as long as 10 days. A further benefit is that during the process of pumping the ink into the fluid membrane, if mistakes are made, the nozzle can actually extract and rewrite the ink as needed.

The researchers believe that this advance in the field of bioprinting will help greatly with the production of complex tissue-like constructs including arteries and tracheae.

And this could have a major impact in terms of regenerative medicine, the scientists say, as well as producing in-vitro tissue models for studies and the likes of disease modeling, or potential applications like drug screening or development.

The researchers note that a commercially available 3D printer has been used in their early experiments thus far, albeit when printing multiple cells, a homemade microuidic nozzle head was employed instead.

See the original post here:
3D printing could have cracked the problem of making human organs - TechRadar

NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2019, and provide a corporate update, at 8:00 a.m., Eastern Standard Time, on Thursday, November 14, 2019.

BrainStorms President & CEO, Chaim Lebovits, will present a corporate update, after which, participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, and Preetam Shah, PhD, Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to: q@brainstorm-cell.com; Questions should be submitted by 5:00 p.m., Eastern Standard Time, Tuesday, November 12.

The investment community may participate in the conference call by dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the Investors & Media page of BrainStorms website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

A webcast replay of the conference call will be available for 30 days on the Investors & Media page of BrainStorms website:

About NurOwnNurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company's website at http://www.brainstorm-cell.com

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Excerpt from:
BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update - GlobeNewswire

Psoriatic arthritis causes joint pain and inflammation, usually in people who already have psoriasis. It is impossible to predict who will get psoriatic arthritis, however, and there is no surefire strategy for preventing it.

About 30% of people with psoriasis eventually develop psoriatic arthritis.

Preventive strategies for psoriasis focus on identifying triggers and treating symptoms early. Doing so may prevent psoriasis from transitioning to psoriatic arthritis.

In this article, learn about treatment and prevention strategies for psoriatic arthritis, as well as the risk factors for developing it.

Doctors do not know how to prevent psoriatic arthritis.

Currently, no treatment can guarantee that a person with psoriasis will not develop this form of arthritis.

Also, because a small number of people develop psoriatic arthritis without skin symptoms of psoriasis, it can be difficult to identify everyone who is at risk.

A 2019 medical review article highlights the many challenges that doctors face in trying to prevent psoriatic arthritis. Doctors do not fully understand how or why the disease progresses or who is at risk.

More research could, one day, answer these questions. For now, controlling the symptoms of psoriasis before it progresses into arthritis may help reduce the severity of both diseases.

People with psoriatic arthritis typically develop symptoms about 10 years after they get psoriasis.

Anyone with concerns about the progression of the disease should speak with a doctor about the outlook and managing the symptoms.

No specific treatment can prevent psoriatic arthritis, but the right treatment may lessen the severity of the disease.

Both psoriasis and psoriatic arthritis are autoimmune diseases, which means that they occur when the body attacks healthy tissue.

People with psoriatic arthritis develop active inflammation in the joints, as well as markers of inflammation in the blood.

Tests for inflammation may help assess whether a person is at risk of psoriatic arthritis, and working to prevent inflammation may help reduce symptoms of the disease.

For people who develop psoriatic arthritis, the right treatment can minimize disease activity. It may also reduce markers of the disease enough to achieve remission.

A 2010 study explored the outcomes of treatment with antitumor necrosis factor alpha which involves using biologic medication to reduce inflammation in people with psoriatic arthritis or rheumatoid arthritis.

The researchers found that, after 1 year of treatment, psoriatic arthritis was in remission in 58% of the people with the disease, compared with 44% of the people with rheumatoid arthritis.

Most people experience psoriatic arthritis as a series of symptom flares. The characteristics of these flares vary from person to person, but many notice a specific pattern.

For example, some people find that psoriasis skin symptoms get worse, or that they feel more fatigued before their joints start to ache.

Tracking symptoms can help a person and their doctor identify the pattern of flares. It may help to take note of meals and new foods, weather changes, stress levels, exercise, and other lifestyle and environmental factors, both between and during flares.

Some common flare triggers include:

Some people find that the following strategies help reduce the severity and frequency of flares:

Some people choose to avoid certain triggering foods or to follow an anti-inflammatory diet.

The Arthritis Foundation recommend eating foods that can reduce inflammation, including:

Reducing salt and alcohol intake may also help curb inflammation. Learn more about an anti-inflammatory diet in this article.

While lifestyle changes can make a big difference, they are not always enough to treat symptoms or prevent flares.

A doctor can offer a wide range of treatments to help with pain and stiffness. Biologic medications, for example, are highly effective for many people.

A doctor may also recommend:

If a person thinks that they may have early symptoms of psoriatic arthritis, they should speak to a doctor.

Also, consult a doctor about:

Psoriatic arthritis damages the joints, intensifying the severity of subsequent flares. Once it happens, arthritis-related joint damage cannot be reversed.

Medication may not cure psoriatic arthritis, but it can prevent joint damage. This means that early, aggressive treatment may offer lasting benefits.

People who develop joint pain or stiffness should see a doctor, even if they do not think that they have psoriasis.

During a person's first few flares, frequent and regular communication with a doctor can help them better understand the disease and identify effective treatments.

Do not stop taking psoriatic arthritis medication without talking to a doctor. When symptoms clear up, it is a sign that the treatment is working, not that it is time to stop the treatment. Some people find that their flares get much worse when they stop using their medication.

Psoriasis and psoriatic arthritis are complex diseases. They likely develop due to a combination of genetics, inflammation, factors such as skin and joint injuries, and specific psoriasis triggers.

There is no psoriatic arthritis prevention strategy, but getting prompt and effective treatment can help reduce the frequency and severity of symptoms.

A rheumatologist can identify risk factors for psoriatic arthritis and help minimize the chances of developing the disease.

However, there is no way to predict who will get psoriatic arthritis and no surefire way to prevent this inflammatory joint disease.

Doctors, loved ones, and support groups can help a person manage stress and their psoriatic arthritis symptoms.

See the article here:
Psoriatic arthritis prevention: Tips and management - Medical News Today

AbbVie blockbuster-to-be Rinvoq only just hit the scene in rheumatoid arthritis, but its already on its way to a second indication.

Thursday, the Illinois drugmaker said its newcomer had hit its primary endpoint in a phase 3 psoriatic arthritis (PsA) trial, topping placebo at reducing symptoms. At Week 12, 57% of patients taking a 15 mg dose and 64% of patients on a 30 mg dose hit ACR20, a benchmark on a commonly used scale from the American College of Rheumatology to measure joint swelling and more. Just 24% of placebo patients reached the same mark.

Full results from the trial, dubbed Select-PsA2, will roll out at a future medical meeting and in a peer-reviewed publication, AbbVie said. Theyll also support regulatory submissions for Rinvoq in PsA, Michael Severino, M.D., company vice chairman and president, said in a statement.

Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies

What is your perspective on offering a DTP option? Share your thoughts for a chance to win a $5 Amazon gift card.

RELATED:AbbVie scores blockbuster approval for RA med Rinvoq, its crucial Humira follow-up

"Too many people living with psoriatic arthritis still fail to achieve their treatment goals, underscoring a clear medical need for additional therapeutic options," he added.

Those therapeutic options have multiplied recently with the advent of the IL-17A class, beginning with a PsA nod for Novartis Cosentyx in early 2016. Eli Lillys Taltz followed up with its own late the following year, and the two have been battling it outin the market ever since.

AbbVie isnt afraid of a little competition in the anti-inflammatory market, though. After all, its positioning Rinvoq as a follow-up to Humira, the worlds best-selling drug. Analysts expect the med to hit $2.2 billion in annual sales per year by 2023, helping AbbVie fill the gap left by Humira biosimilars.

RELATED:AbbVie's Rinvoq label portends safety warnings for future JAKsincluding Gilead's

Theres just one potential snag: Rinvoq is a member of the JAK inhibitor class, which has recently been plagued by safety issues.

Follow this link:
AbbVie eyes 2nd Rinvoq nod as it hits its marks in psoriatic arthritis - FiercePharma

Conquering Arthritis Meet the University of Arizona Arthritis Center Researchers will be presented Wednesday, Nov. 6, 6-7:15 p.m., at the Health Sciences Innovation Building on the UA Health Science campus, 1670 E. Drachman St., Tucson.

This event features a look into the future of care, prevention, and ultimately a cure, for this debilitating disease. A panel discussion with UArizona Arthritis Center Director C. Kent Kwoh, MD, pain management specialist Mohab Ibrahim, PhD, MD, and mind-body medicine pioneer Esther Sternberg, MD, will follow the researcher open house and poster displays.

The U.S. Centers for Disease Control and Prevention estimate nearly 55 million Americans have some form of arthritis, including almost half of those over age 65. Arthritis affects more women than men and can affect children as young as 6 months old. It is the leading cause of disability in the United States.

The UArizona Arthritis Center is Arizonas only multi-disciplinary center of excellence dedicated to research and education into the causes, treatments and eventually a cure for arthritis. The center conducts basic, translational and epidemiological research to understand why patients get arthritis, the risk factors for who gets arthritis and analyzes the outcomes to understand how arthritis impacts the patients quality of life.

Featured UArizona Arthritis Center researchers who will present at the event include:

Research topics will include:

Seating for the lecture is limited and prior registration is requested. For more information or to register, visit the UArizona Arthritis Center website, arthritis.arizona.edu, or call 520-626-5040 or email [emailprotected]

Free parking is available after 5 p.m. in the Lot Specific 2012 parking lot next to the Health Sciences Innovation Building and the Lot Specific 2147 parking lot across the street on Cherry Avenue between Helen and Mabel Streets, as well as in all Lot Specific parking lots on the UArizona Health Sciences campus and the Health Sciences Garage (formerly the Banner University Medical Center Tucson Visitor/Patient Parking Garage) at 1501 N. Campbell Ave. For disabled parking, or drop off location next to the Health Sciences Innovation Building, please email [emailprotected], or call 520-626-5040.

If you have questions concerning access, wish to request a Sign Language interpreter or disability-related accommodations, contact Tracy Shake, 520-626-5040, email: [emailprotected]

The lecture is part of the Living Healthy with Arthritis series of free monthly talks presented by the UArizona Arthritis Center at the UArizona College of Medicine Tucson and supported through the Susan and Saul Tobin Endowment for Research and Education in Rheumatology.

Go here to see the original:
Meet University of Arizona Arthritis Center researchers - Jewish Post

INTRODUCTION:

Pain control is one of the most important aspects ofrheumatoid arthritis(RA) management from the patients perspective. Newer generations of RA treatment including tumor necrosis factor inhibitor (TNFi) have the potential to alleviate pain and thus reduce opioid utilization. However, patterns of opioid utilization before and after TNFi initiation have not been well characterized. This study aims to examine multiple measures of change in opioid utilization after the initiation of TNFi.

Patients aged 18years with RA and 24months continuous enrollment between January 2007 and December 2015 who newly initiated a TNFi in IQVIA Health Plan Claims Data were included in our study. Opioid utilization at baseline and during follow-up were identified and compared.

Of 2330 patients with RAthat were included in the study, 38.8% of patients used opioids in both baseline and follow-up periods. From pre-index to post-index, the proportion of patients receiving any opioid decreased from 54.0 to 51.0%. In addition, the proportion of those who received 50mg median daily MED decreased from 12.6 to 10.6% during pre-post periods.

This real-world study of commercially insured patients with RA suggests that opioid use among thesepatients is prevalent. There was a small decrease in overall opioid utilization after TNFi initiation.

See more here:
Changes in Opioid Utilization Following Tumor Necrosis Factor Inhibitor Initiation in Patients with Rheumatoid Arthritis - DocWire News

An established carver in Happy Valley-Goose Bay didn't give up his craft after losing the sight in one of his eyes. In fact, he's continuing to create pieces of art in spite of it.

John Neville spent his summer crafting over 300 carvings in a shack outside his house, something he finds to be therapeutic.

"I love carving because it's good for the mind," Neville said at he satin his work shed surrounded by his work.

Neville, originally from Black Tickle,has spent 45 years of his life doing what he loves.

Neville said it has been a difficult year for many reasons as he struggled with depression as well as the loss ofsight in one of his eyes.

He had a stroke in his sleep in January of 2017, resulting in vision loss.

"It's been a hard struggle, knowing that I had good eyesight and now I only got one [good] eye."

Watch the video above to hear John Neville's story and see his carvings

"Close up me eyes aren'tthat good. Even me good eye's not good close up," he said.

Neville said he isn't one to take medication for an illness, and instead uses carving to heal him.

"Carving is my medicine, it was always my medicine when I get down and that medicine is going to bring me back up and make me the same fella I used to be."

Read more stories by CBC Newfoundland and Labrador

Link:
Loss of vision doesn't keep this Happy Valley-Goose Bay carver from his craft - CBC.ca

Mutations in genes related to the immune systems first line of defense are associated with a greater likelihood of more severe forms of multiple sclerosis (MS) linked to faster vision loss, a team led by Johns Hopkins Medicine researchers report.

Combining high-resolution eye scans and genetic tests, researchers identified three genes involved in the complement immune pathway that are tied to a more rapid degeneration of nervous tissue in the eye and loss of sight.These genetic variants (mutations) could serve as markers for monitoring MS and predicting its severity, the researchers said.

Their study, Early complement genes are associated with visual system degeneration in multiple sclerosis, was published in the journal Brain.

In MS, the bodys immune system mistakenly attacks the myelin sheaths of nerve fibers the fat-rich coat around nerve fibers resulting in inflammation, degeneration, nerve cell death, and ultimately disrupting communication between the brain and spinal cord, and the rest of the body.

Vision problems are among disease symptoms.

Although several genetic risk factors are known to predispose people to MS, no mutations have been linked with MS severity. This gap results in part due to the inability of current clinical scales to detect early degenerative changes that underlie disease progression.

Optical coherence tomography(OCT) is a noninvasive imaging test that enables doctors to see eye structures with exquisite detail. For instance, it is used to look at nervous tissue of the retina in the back of the eye, and check for signs of disease. Taking advantage of OCTs potential, scientists are exploring it as an imaging tool to measure nerve cell degeneration at early stages in MS, as well as disease progression.

To discover possible genetic predictors of MS severity, Peter Calabresi, MD, the studys senior leader and a professor at Johns Hopkins University, and histeam assessed 374 patients (average age of 43 ) with all MS types using OCT, and crossed this information with genetic tests performed on patients blood samples.

Although we have treatments for the type of MS where symptoms come on in bursts called relapsing-remitting MS we dont have any way to stop the kind of MS in which the nerve cells start to die, known as progressive MS, Calabresi, who is a director of the Johns Hopkins Precision Medicine Center of Excellence for MS, said in a universitynews release.

OCT was used to measure thinning (degeneration) in the layer of nerve cells known as ganglion cells in the retina over time. Onaverage, 4.6 OCT scans were performed on each patient between 2010 and 2017.

Scans showed that MS patients lost an average of 0.32 micrometers (one-millionth of a meter) of retinal nervous tissue per year.

Researchers then searched for mutations in patients with the fastest retinal deterioration rates, and identified 23 DNA variations. They all mapped to gene C3, which codes for a protein involved in the complement pathway of the immune system.

The team employed a similar approach to a separate group of 835 MS patients, but instead of searching for OCT degeneration, they now looked for genetic factors in patients with a rapidly declining ability to see faint letters,mimicking low light conditions using the low-contrast letter acuity (LCLA) test.

Researchers based their analysis on this vision test because it correlates with clinical disability and nerve cell loss in MS, and is emerging as a valid clinical measure of the disease.

Specific mutations in the genes C1QA and CR1 were more frequent in patients whose visual ability deteriorated faster. Those with certain variants in C1QA were 71% more likely to develop difficulty detecting visual contrast, while those with CR1 variants were at a 40% greater risk of such problems.

Like C3, both C1QAand CR1 are genes involved in the complement pathway.

These results showed that early complement pathway gene variants were consistently associated with structural and functional measures of multiple sclerosis severity. These results from unbiased analyses are strongly supported by several prior reports that mechanistically implicated early complement factors in neurodegeneration, the researchers wrote.

We believe that our study opens up a new line of investigation targeting complement genes as a potential way to treat disease progression and nerve cell death, Calabresi said in the release.

[O]ther researchers discovered that complement proteins bind to the connections between neurons and helps them grow in specific directions. But, too much complement was found to causes damage to the nerve cells, eventually killing them. Our findings fit well into this system, he added.

The team believes that these three genes could also be used as markers to monitor and predict disease progression and severity.

Our next step will be to repeat these studies in larger populations, said Kathryn Fitzgerald, ScD,a Johns Hopkins professor and the studys lead author of the study.

Animal studies are likely to follow, to detail how the complement system is involved in neurodegeneration during MS. From there we can possibly think about how to design new therapies, Fitzgerald said.

Ana is a molecular biologist with a passion for discovery and communication. As a science writer she looks for connecting the public, in particular patient and healthcare communities, with clear and quality information about the latest medical advances. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in genetics, molecular biology, and infectious diseases

Total Posts: 1,053

Patrcia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

Continue reading here:
Mutations in 3 Genes Linked to MS Severity and Vision Loss in Hopkins Study - Multiple Sclerosis News Today

It's a phone call no one ever wants to answer. "He said 'Scotty's come face-to-face with a suicide car bomb and it exploded. There's shrapnel in both of his eyes and I don't know if he's going to live'," Tiffany Smiley recalled.In April of 2005, Tiffany's husband Scott Smiley was serving in Iraq. That's when a car bomb took his vision away and could have taken his life. "My eyesight was taken when he blew his car up. And then I found myself woken up in Walter Reed Army Medical Center blind for the rest of my life," Scott said.His wife, Tiffany, said in the moment, her world blew into a million pieces. She said she was presented paperwork to begin his medical retirement. She chose not to sign them.The doctors said 'Mrs. Smiley, you have power of attorney. Sign the paperwork to begin his medical retirement.' And I looked at them and I said 'no'," Tiffany said.Those papers would have retired Scott from the thing that gave him purpose. She couldn't do that."I took the paperwork, I put it in a drawer and I truly believed that there had to be another path," Tiffany added.Scott said that the journey has been tough, but he wouldn't trade it for anything. "It was my wife and family and friends that stood by me and enabled me, not only to forgive but to begin my recovery," Scott explained."He went on to become the first blind active duty officer to continue service to our country. He wrote a book, became a teacher, we had three beautiful boys along this journey," Tiffany said. It's the Smiley's story of perseverance that has impacted so many people.

It's a phone call no one ever wants to answer.

"He said 'Scotty's come face-to-face with a suicide car bomb and it exploded. There's shrapnel in both of his eyes and I don't know if he's going to live'," Tiffany Smiley recalled.

In April of 2005, Tiffany's husband Scott Smiley was serving in Iraq.

That's when a car bomb took his vision away and could have taken his life.

"My eyesight was taken when he blew his car up. And then I found myself woken up in Walter Reed Army Medical Center blind for the rest of my life," Scott said.

His wife, Tiffany, said in the moment, her world blew into a million pieces. She said she was presented paperwork to begin his medical retirement.

She chose not to sign them.

The doctors said 'Mrs. Smiley, you have power of attorney. Sign the paperwork to begin his medical retirement.' And I looked at them and I said 'no'," Tiffany said.

Those papers would have retired Scott from the thing that gave him purpose. She couldn't do that.

"I took the paperwork, I put it in a drawer and I truly believed that there had to be another path," Tiffany added.

Scott said that the journey has been tough, but he wouldn't trade it for anything.

"It was my wife and family and friends that stood by me and enabled me, not only to forgive but to begin my recovery," Scott explained.

"He went on to become the first blind active duty officer to continue service to our country. He wrote a book, became a teacher, we had three beautiful boys along this journey," Tiffany said.

It's the Smiley's story of perseverance that has impacted so many people.

Originally posted here:
Army Major shares story of loss and triumph - KETV Omaha